Nelly Selloum-Etienne

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.

Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: January 02, 2024

Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.

Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: December 06, 2023

Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α.

Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α.

Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: November 21, 2023

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction.

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction.

Journal: Cells
Published: December 02, 2022

Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.

Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.

Journal: Pharmaceutics
Published: July 26, 2022

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.

Journal: Journal of cancer research and clinical oncology
Published: December 12, 2021

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.

Journal: Cancers
Published: October 25, 2021

Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma.

Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 28, 2021

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Journal: Cancers
Published: May 03, 2021

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.

Journal: Cancers
Published: February 12, 2021

Exposure to Endocrine Disrupting Chemicals and Risk of Breast Cancer.

Exposure to Endocrine Disrupting Chemicals and Risk of Breast Cancer.

Journal: International journal of molecular sciences
Published: October 27, 2020

Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.

Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.

Journal: Chembiochem : a European journal of chemical biology
Published: September 02, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026